TopSustainabilitySustainability Management

We will promote sustainability in the manner unique to JCR as a specialty pharma in the rare disease arena.

Basic Approach to Sustainability

Since its inception in 1975, JCR has sought to create groundbreaking therapeutics that respond to unmet medical needs, particularly in the rare disease field, under its corporate philosophy of “Contributing towards people’s healthcare through pharmaceutical products.” To this end, we have been harnessing forward-looking biotechnologies, as well as technologies for cell therapy and regenerative medicine.
The global environment and conditions and issues facing society have been changing year by year, but JCR believes that it is crucial to create sustained corporate value through its business activities as a pharmaceutical manufacturer and contribute to the development of a sustainable society, and is implementing activities in the core areas of Rare Diseases, Environment, Society, and Corporate Governance. Rare Diseases, in particular, are closely related to JCR’s business activities and are a domain to which JCR can especially contribute. In addition to developing treatments for ultra-rare diseases and building new business models, JCR has also worked to improve access to medicines. We will proactively engage in things that only JCR can provide even for ultra-rare diseases where there are only few patients as we aim to achieve a society where no one will be left behind.

Structure for Promoting Sustainability

In July 2022, JCR established the Sustainability Advisory Committee, Sustainability Committee and Environmental Committee to enable in-depth discussions and formulating strategies in close alignment with management in response to the ever-changing social and business environment and challenges surrounding JCR. JCR will continue to work as one team, driven by a sense of purpose in the rare disease field, to pursue sustainability in the manner unique to JCR.

Sustainability Advisory Committee
The members of this Committee are Internal Directors, Independent Outside Directors, and Corporate Officers.
The Committee provides feedback on matters presented to the Board of Directors by the Sustainability Committee.
Sustainability Committee
Chaired by the director in charge of sustainability, members will be employees appointed from each business division. This Committee will identify material issues, discuss and propose ESG-related initiatives, monitor progress, and report findings to the Board of Directors.
Environmental Committee
Members will be Internal Directors and employees appointed from each business division. They will consider the environmental impact of business activities as a long-term risk factor affecting business and society, and practice environmentally friendly business activities.

Core Sustainability Initiatives

Rare Diseases
  • Development of drugs for ultra-rare diseases and construction of new business models
  • Efforts to improve access to medicines (Named Patient Supply) to deliver innovative medicines to people around the world
  • Investigation and implementation of measures to reduce environmental impact through business activities
  • Promote environmentally friendly procurement on the premise of ensuring the quality and stable supply of pharmaceuticals
  • Address the challenge of unmet medical needs by creating platform technologies
  • Develop human resources so that each member of “Team JCR” can shine in their own station
Corporate Governance
  • Pursue governance in line with the Company’s growth
  • Ensure thorough compliance and strengthen risk management

Addressing the SDGs

JCR believes that partnership and cooperation with the international community are the most important priorities for realizing sustainability. JCR proactively conducts sustainability initiatives, in keeping with the spirit of the SDGs of “no one will be left behind.” It shares with and returns to a wide range of stakeholders the achievements of these efforts.

Process for Identifying Materiality
(Material Issues)

JCR believes that it is crucial to continue pursuing the sustained creation of corporate value through its business activities, thereby contributing to a sustainable society. To that end, JCR identifies the materiality issues it should address through the process outlined to the right.

List materiality issues
Derive materiality issues by referring to international guidelines, principles and frameworks, as well as conditions and challenges faced by the pharmaceutical industry, and from the perspectives of what JCR is uniquely capable of doing and what it should be doing.
Assess materiality
Assess the importance of the materiality issues derived in 1. from the perspective of their impact on society and the environment as well as their impact on JCR’s business.
Assign priority to materiality issues
Based on the assessment in 2., organize materiality issues into categories and assign priority to highly important materiality issues for JCR from a long-term perspective, in light of JCR’s corporate philosophy, purpose, business activities, and Midterm Business Plan.
Determine materiality
The issues identified in 3. are discussed and approved by the Board of Directors and are established as JCR’s material issues. The identified materiality is explained and shared internally so that each employee can take ownership of each issue, and further enhancements are made. In addition, specific materiality issues are shared with a wide range of stakeholders through disclosure via JCR’s website and other channels.